Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.35 |
| ▸ | LPL | P06858 | 7/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798379 | 0.91 | LPL (0.38) | PRMT6EPHX2NOS1LIPGLPL | |
| SCHEMBL3802884 | 0.89 | NOS3 (0.42) | PRMT6EPHX2NOS3NOS1LIPG | |
| SCHEMBL3796751 | 0.81 | CHRNB2 (0.37) | PRMT6DYRK1ALIPGLPLF11 | |
| SCHEMBL553104 | 0.77 | LPL (0.43) | DYRK1ALIPGLPLF11RET | |
| SCHEMBL552697 | 0.76 | KCNH2 (0.38) | DYRK1ALIPGLPLF11FFAR1 | |
| SCHEMBL28563382 | 0.75 | LIPG (0.42) | LIPGLPLF11FFAR1DGAT1 | |
| SCHEMBL3803519 | 0.75 | MKNK1 (0.45) | LIPGLPLF11FFAR1DGAT1 | |
| SCHEMBL3796275 | 0.75 | LIPG (0.62) | LIPGLPLDGAT1 | |
| SCHEMBL3798360 | 0.75 | LIPG (0.49) | PRMT6EPHX2LIPGLPLF11 | |
| SCHEMBL12373176 | 0.75 | LPL (0.44) | LIPGLPLF11FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | PRMT6 1956/4885EPHX2 3222/4885NOS3 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.